Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
FDF
0
FDA Orange Book
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 111 In -pentetreotide
2. 111-indium-pentetreotide
3. In-111 Pentetreotide
4. Indium In 111 Pentetreotide
5. Indium Ln-111 Pentetreotide
6. Indium-pentetreotide
7. Octreoscan
8. Octreoscan 111
9. Pentetreotide
1. Pentetreotide
2. 138661-02-6
3. Pentetreotide (jan/inn)
4. Schembl1651014
5. Schembl23309836
6. 2-[2-[[2-[[1-[[10-(4-aminobutyl)-16-benzyl-4-(1,3-dihydroxybutan-2-ylcarbamoyl)-7-(1-hydroxyethyl)-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-(carboxymethyl)amino]ethyl-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic Acid
7. Ft-0701094
8. D01859
Molecular Weight | 1394.6 g/mol |
---|---|
Molecular Formula | C63H87N13O19S2 |
XLogP3 | -9.4 |
Hydrogen Bond Donor Count | 17 |
Hydrogen Bond Acceptor Count | 25 |
Rotatable Bond Count | 34 |
Exact Mass | 1393.56825994 g/mol |
Monoisotopic Mass | 1393.56825994 g/mol |
Topological Polar Surface Area | 545 Ų |
Heavy Atom Count | 97 |
Formal Charge | 0 |
Complexity | 2590 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 10 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Pentetreotide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pentetreotide, including repackagers and relabelers. The FDA regulates Pentetreotide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pentetreotide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Pentetreotide supplier is an individual or a company that provides Pentetreotide active pharmaceutical ingredient (API) or Pentetreotide finished formulations upon request. The Pentetreotide suppliers may include Pentetreotide API manufacturers, exporters, distributors and traders.
click here to find a list of Pentetreotide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pentetreotide DMF (Drug Master File) is a document detailing the whole manufacturing process of Pentetreotide active pharmaceutical ingredient (API) in detail. Different forms of Pentetreotide DMFs exist exist since differing nations have different regulations, such as Pentetreotide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pentetreotide DMF submitted to regulatory agencies in the US is known as a USDMF. Pentetreotide USDMF includes data on Pentetreotide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pentetreotide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pentetreotide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Pentetreotide Drug Master File in Japan (Pentetreotide JDMF) empowers Pentetreotide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Pentetreotide JDMF during the approval evaluation for pharmaceutical products. At the time of Pentetreotide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Pentetreotide suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pentetreotide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pentetreotide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pentetreotide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pentetreotide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pentetreotide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pentetreotide suppliers with NDC on PharmaCompass.
Pentetreotide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pentetreotide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pentetreotide GMP manufacturer or Pentetreotide GMP API supplier for your needs.
A Pentetreotide CoA (Certificate of Analysis) is a formal document that attests to Pentetreotide's compliance with Pentetreotide specifications and serves as a tool for batch-level quality control.
Pentetreotide CoA mostly includes findings from lab analyses of a specific batch. For each Pentetreotide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pentetreotide may be tested according to a variety of international standards, such as European Pharmacopoeia (Pentetreotide EP), Pentetreotide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pentetreotide USP).
LOOKING FOR A SUPPLIER?